

21st Century Therapeutics, Inc.

1366 HILTON RD. FERNDALE, MI 48220 USA (248) 545-0595 21-cti.com

For Immediate Release

May 1, 2013

Pharmaceutical Research Firm Receives a Phase I SBIR Grant from NIH

Ferndale based 21^{st} Century Therapeutics, Inc. (21CTI) received a one-year research grant of \$276 K from National Institutes of Health (NIH) to study a small-molecule Tumor Necrosis Factor- α (TNF- α) to treat oxaplatin-induced thrombocytopenia. According to 21CTI's CEO, Dr. Frederick Valeriote, this is the fourth SBIR grant received by 21CTI.

"This research grant will help us further the preclinical development of UTL-5g as a chemoprotector", said Valeriote. According to 21CTI's president and the Principal Investigator of this study, Dr. JJ Shaw, oxaliplatin is a platinum drug that is more widely prescribed than cisplatin. Our recent studies showed that pretreatment of UTL-5g restored/increased platelet number reduced by cisplatin. Therefore, this Phase I SBIR grant will be used to show the feasibility of using UTL-5g to treat thrombocytopenia induced by oxaliplatin. If successful, a Phase II grant will be applied to continue the preclinical development.

21CTI is a private pharmaceutical discovery and development company, specializing in cancer and immune-mediated diseases. In addition to this project, the Company has several projects under discovery or development,

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchanges rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. 21CTI's management does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact: Office (248) 545-0595, Frederick Valeriote (586) 863-8298, JJ Shaw (734) 330-6052

Website: www.21-cti.com

e-mail: jshaw@21-cti.com or jiajiushaw@gmail.com